Application of a rat model of streptococcal shock to evaluate on-line hemoperfusion and removal of circulating superantigens

Critical Care Medicine

Volumn 31, Issue 1, 2003, Pages 171-178

  Fenwick, Peter ^a   Ryan, Calvin ^a   Sriskandan, Shiranee ^a   Cohen, Jonathan ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Extracorporeal therapy; Hemoperfusion; Shock; Streptococcus; Superantigen

Indexed keywords

EXOTOXIN; POLYPROPYLENE; POLYSTYRENE; PYROGEN; STREPTOCOCCAL PYROGENIC EXOTOXIN A; SUPERANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EVALUATION; EXTRACORPOREAL CIRCULATION; HEMOPERFUSION; NONHUMAN; ONLINE SYSTEM; PRIORITY JOURNAL; RAT; SHOCK; STREPTOCOCCUS; SUPERNATANT; SURVIVAL;

ANIMALS; BACTERIAL PROTEINS; EXOTOXINS; FEMALE; HEMODYNAMIC PROCESSES; HEMOPERFUSION; INTERLEUKIN-6; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC; STATISTICS, NONPARAMETRIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SUPERANTIGENS;

EID: 0037253251     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301000-00027     Document Type: Article

References (38)

1. Stevens DL, Tanner MH, Winship J, et al: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7
2. Demers B, Somor AE, Vellend H, et al: Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792-800
3. Chelsom J, Halstensen A, Haga T, et al: Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344:1111-1115
4. Breathnach AS, Eykyn SJ: Streptococcus pyogenes bacteraemia: A 27-year study in a London teaching hospital. Scand J Infect Dis 1997; 29:473-478
5. Mascini EM, Jansze M, Schellekens JF, et al: Invasive group A streptococcal disease in The Netherlands: Evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis 2000; 181:631-638
6. Bannan J, Visvanathan K, Zabriskie JB: Structure and function of streptococcal and staphylococcal superantigens in septic shock. Infect Dis Clin North Am 1999; 13:387-396
7. Cunningham MW: Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511
8. Norrby-Teglund A, Kotb M: Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000; 49:849-852
9. Sriskandan S, Moyes D, Cohen J: Detection of circulating bacterial superantigen and lymphotoxin-α in patients with streptococcal toxic-shock syndrome. Lancet 1996; 348:1315-1316
10. Miwa K, Fukuyama M, Kunitomo T, et al: Rapid assay for detection of toxic shock syndrome toxin 1 from human sera. J Clin Microbiol 1994; 32:539-542
11. Visvanathan K, Charles A, Bannan J, et al: Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 2001; 69:875-884
12. Kaul R, McGeer A, Norrby-Teglund A, et al: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: A comparative observational study. Clin Infect Dis 1999; 28:800-807
13. Arad G, Levy R, Hillman D, et al: Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6:414-421
14. Sriskandan S, Unnikrishnan M, Krausz T, et al: Molecular analysis of the role of streptococcal pyrogenic exotoxin A (SPEA) in invasive soft tissue infection due to Streptococcus pyogenes. Mol Microbiol 1999; 33:778-790
15. Scharfman WB, Tillotson JR, Taft EG, et al: Plasmapheresis for meningococcemia with disseminated intravascular coagulation. N Engl J Med 1979; 300:1277-1278
16. Cohen J, Ryan C, Pusey C, et al: Protection from endotoxemia: A rat model of plasmapheresis and specific adsorption with polymyxin B. J Infect Dis 1987; 155:690-695
17. Aoki H, Kodama M, Tani T, et al: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167:412-417
18. Nakamura T, Ebihara I, Shimada N, et al: Effects of hemoperfusion with polymyxin B-immobilized fibre on serum neopterin and soluble interleukin-2 receptor concentrations in patients with septic shock. J Infect 1998; 37:241-247
19. Drenger B, Israeli A, Or R, et al: Plasmapheresis for streptococcal sepsis? Lancet 1985; 2:943
20. Stegmayr B, Björck S, Holm S, et al: Septic shock induced by group A streptococcal infection: Clinical and therapeutic aspects. Scand J Infect Dis 1992; 24:589-597
21. Shimamura M, Teramoto K, Yoshioka T, et al: Polystyrene-based functional fibers. In: Lewin M, Preston J (Eds). Handbook of Fiber Science and Technology. New York, Marcel Dekker, 1989
22. Miwa K, Fukuyama M, Sakai R, et al: Sensitive enzyme-linked immunosorbent assays for the detection of bacterial superantigens and antibodies against them in human plasma. Microbiol Immunol 2000; 44:519-523
23. Brun-Buisson C, Doyon F, Carlet J, et al: Incidence, risk factors and outcome of severe sepsis and septic shock in adults: A multi-center prospective study in intensive care units. JAMA 1995; 274:968-974
24. Rangel-Frausto M: The epidemiology of bacterial sepsis. Infect Dis Clin North Am 1999; 13:299-312
25. Opal SM, Cohen J: Are there fundamental differences of clinical relevance between Gram positive and Gram negative bacterial sepsis? Crit Care Med 1999; 27:1608-1616
26. Sriskandan S, Cohen J: Gram positive sepsis: Mechanisms and differences from Gram negative sepsis. Infect Dis Clin North Am 1999; 13:397-412
27. Kotb M: Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-426
28. Ulrich RG, Bavari S, Olson MA: Bacterial superantigens in human disease: Structure, function and diversity. Trends Microbiol 1995; 3:463-468
29. Lavoie PM, Thibodeau J, Erard F, et al: Understanding the mechanism of action of bacterial superantigens from a decade of research. Immunol Rev 1999; 168:257-269
30. Visvanathan K, Zabriskie JB: The role of bacterial superantigens in sepsis and treatment implications. Curr Opin Crit Care 2000; 6:312-316
31. De Kimpe SJ, Kengatharan M, Thiemermann C, et al: The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA 1995; 92:10359-10363
32. Piepmeier E Jr, Hammett-Stabler C, Price M, et al: Myositis and fasciitis associated with group A beta hemolytic streptococcal infections: Development of a rabbit model. J Lab Clin Med 1995; 126:137-143
33. Saetre T, Hoiby EA, Aspelin T, et al: Acute serogroup A streptococcal shock: A porcine model. J Infect Dis 2000; 182:133-141
34. Taylor-FB J, Bryant AE, Blick KE, et al: Staging of the baboon response to group A streptococci administered intramuscularly: A descriptive study of the clinical symptoms and clinical chemical response patterns. Clin Infect Dis 1999; 29:167-177
35. Wayte J, Silva AT, Krausz T, et al: Observations on the role of tumor necrosis factor α in a routine model of shock due to Streptococcus pyogenes. Crit Care Med 1993; 21:1207-1212
36. Sriskandan S, Moyes D, Buttery LD, et al: Streptococcal pyrogenic exotoxin A release, distribution and role in a murine model of fasciitis and multi-organ failure due to Streptococcus pyogenes. J Infect Dis 1996; 173:1399-1407
37. Saetre T, Hoiby EA, Aspelin T, et al: Aminoethyl-isothiourea inhibits the increase in plasma endothelin-1 caused by serogroup A streptococci and prolongs survival in rat peritoneal sepsis. Shock 2000; 15:446-452
38. Miwa K, Fukuyama M, Ida N, et al: Preparation of superantigen-absorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 2003 (In Press)